Valuation: SAB Biotherapeutics, Inc.

Market Cap 266M 241M 223M 201M 380M 24.83B 394M 2.69B 1.06B 13.4B 997M 976M 42.33B P/E 2026 *
-3.08x
P/E 2027 * -4.13x
Enterprise Value -6.64M -6.03M -5.57M -5.02M -9.48M -620M -9.84M -67.07M -26.53M -335M -24.9M -24.38M -1.06B EV / Sales 2026 *
-
EV / Sales 2027 * -458x
Free-Float
96.2%
Yield 2026 *
-
Yield 2027 * -
1 day+7.80%
1 week+0.64%
Current month-6.57%
1 month+20.38%
3 months-17.41%
6 months-12.08%
Current year-16.31%
1 week 2.85
Extreme 2.85
3.22
1 month 2.44
Extreme 2.44
3.4
Current year 2.44
Extreme 2.44
5.15
1 year 2.44
Extreme 2.44
5.15
3 years 1
Extreme 1
9.72
5 years 1
Extreme 1
120.9
10 years 1
Extreme 1
129
Manager TitleAgeSince
Chief Executive Officer 60 2014-06-30
Chief Executive Officer 51 2024-02-01
Director of Finance/CFO 40 2024-08-11
Director TitleAgeSince
Chairman 51 2021-10-21
Director/Board Member 65 2019-10-21
Director/Board Member 70 2021-10-21
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Tax

Chief Technology Officer

-473 0.0006%
3/24/26 Tax

Chief Technology Officer

988 0.0021%
2/5/26 Free

Chief Executive Officer

4,800,000 10.0826%
Change 5-day change 1-year change 3-year change Capi.($)
+8.14%+0.64%-19.95%-62.46% 266M
-1.34%-4.12%+53.70%+68.83% 66.37B
+1.08%-1.26%+9.61%+91.79% 58.86B
+0.68%+0.54%+26.08%+86.79% 55.22B
-2.25%-4.07%+10.71%+114.45% 47.21B
-0.71%-6.95%+17.56%+24.43% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.85%-11.72%+126.01%+634.08% 35.19B
-0.17%-1.94%+82.25%+57.30% 32.66B
-1.43%-1.37%-40.93%+383.73% 26.73B
Average -0.07%-3.00%+27.98%+144.02% 40B
Weighted average by Cap. -0.80%-2.92%+33.33%+142.33%

Financials

2026 *2027 *
Net sales - 62.5K 56.74K 52.41K 47.28K 89.26K 5.84M 92.68K 632K 250K 3.15M 234K 230K 9.96M
Net income -89.89M -81.6M -75.38M -68.01M -128M -8.4B -133M -908M -359M -4.53B -337M -330M -14.32B -104M -94.5M -87.3M -78.75M -149M -9.73B -154M -1.05B -416M -5.25B -391M -382M -16.58B
Net Debt -272M -247M -228M -206M -389M -25.45B -404M -2.75B -1.09B -13.73B -1.02B -1B -43.39B -294M -267M -247M -223M -420M -27.5B -437M -2.97B -1.18B -14.84B -1.1B -1.08B -46.89B
Projected Income Statement - Annual - SAB Biotherapeutics, Inc.
Logo SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Employees
86
Date Price Change Volume
26-11-18 US$3.115 +5.59% 113,905
26-11-17 US$2.950 -1.67% 368,267
26-11-16 US$3.000 +1.35% 388,165
26-11-13 US$2.960 -3.90% 658,118
26-11-12 US$3.080 -0.96% 2,111,559
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SAB Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.950USD
Average target price
11.64USD
Spread / Average Target
+294.45%
  1. Stock Market
  2. Stocks
  3. SABS Stock